KM Research Hub
← 返回论文库
已完成 入排:排除 图源:可得 入排置信度 0.98

Long-term efficacy of tafamidis in patients with transthyretin amyloid cardiomyopathy by National Amyloidosis Centre stage.

Thibaud Damy, Rong Wang, Mathew S Maurer, Julian D Gillmore, Marianna Fontana

Eur J Heart Fail 27(12) 2998-3009

PMID40488446
PMCIDPMC12803551
DOI10.1002/ejhf.3696
发表日期2025-06-09
入排依据:未发现恶性肿瘤人群证据。
摘要

摘要

AIMS: Tafamidis is an approved treatment for patients with transthyretin amyloid cardiomyopathy (ATTR-CM) based on the 30-month Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT). This post-hoc analysis evaluated outcomes in ATTR-ACT and its long-term extension study (LTE) by baseline National Amyloidosis Centre (NAC) stage. METHODS AND RESULTS: Patients received either the approved dose of tafamidis 80 mg or placebo in ATTR-ACT and tafamidis in the LTE. All-cause and cardiovascular (CV)-related mortality, CV-related hospitalizations, and Kansas City Cardiomyopathy Questionnaire overall summary and clinical summary (KCCQ-OS/CS) scores were assessed up to 90 months of follow-up. Of 353 patients, 350 were evaluable for NAC staging. At baseline, 42%, 38%, and 20% were NAC stage I, II, and III, respectively. At the end of study, all-cause mortality was lower in the continuous tafamidis versus placebo to tafamidis groups at NAC stages I (36% vs. 61%; hazard ratio [HR] 0.43, p < 0.001) and II (55% vs. 74%; HR 0.51, p = 0.003); with a numerical trend at stage III (69% vs. 88%; HR 0.75, p = 0.298). Survival curves diverged early in patients at NAC stage I, but later at higher stages. Similar patterns were observed for CV-related mortality. Continuous tafamidis versus placebo to tafamidis groups at NAC stages I/II had lower CV-related hospitalization rates and frequently smaller declines in KCCQ-OS/CS scores over follow-up; with favourable trends at stage III. CONCLUSIONS: Tafamidis treatment reduced the risk of mortality and hospitalization in patients with NAC stages I/II ATTR-CM, with favourable trends at stage III. This illustrates the importance of early diagnosis and initiation of disease-modifying therapy. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT01994889, NCT02791230.

KM 提取结果

2 个 Figure · 6 个 KM 面板

进入结果中心
KM Figure3 个面板

Figure 2

Figure 2 Kaplan–Meier curves of all‐cause mortality in patients with baseline National Amyloidosis Centre (NAC) stage I–III transthyretin amyloid cardiomyopathy. ATTR‐ACT, Tafamidis in Transthyretin Cardiomyopathy Clinical Trial; CI, confidence interval; EOS, end of study; LTE, long‐term extension study.

A

all-cause mortality

Figure 2 · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 1:extreme upward reversal曲线 2:extreme upward reversal
查看结果
B

all-cause mortality

Figure 2 · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 1:extreme upward reversal
查看结果
C

all-cause mortality

Figure 2 · Panel C

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel C 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
KM Figure3 个面板

Figure 3

Figure 3 Kaplan–Meier curves of cardiovascular‐related mortality in patients with baseline National Amyloidosis Centre (NAC) stage I–III transthyretin amyloid cardiomyopathy. ATTR‐ACT, Tafamidis in Transthyretin Cardiomyopathy Clinical Trial; CI, confidence interval; EOS, end of study; LTE, long‐term extension study.

A

cardiovascular-related mortality

Figure 3 · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 2:extreme upward reversal
查看结果
B

cardiovascular-related mortality

Figure 3 · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 1:extreme upward reversal
查看结果
C

cardiovascular-related mortality

Figure 3 · Panel C

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel C 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
其他 Figure(1,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1 Patients in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR‐ACT) and the long‐term extension study (LTE) included in this post‐hoc analysis. NAC, National Amyloidosis Centre. *Tafamidis meglumine 20 mg is not an approved treatment for patients with transthyretin amyloid cardiomyopathy. In this study, the main analysis included patients who received the approved dose of tafamidis meglumine 80 mg or placebo in ATTR‐ACT and tafamidis in the LTE. The sensitivity and supplementary analyses included patients who received tafamidis 80/20 mg (pooled) or placebo in ATTR‐ACT and tafamidis in the LTE. Of 176 patients randomized to tafamidis meglumine 80 mg in ATTR‐ACT, three did not have both a baseline estimated glomerular filtration rate and N‐terminal pro‐B‐type natriuretic peptide concentration to allow NAC staging.
非 KM Figure